Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
|
|
GUIDED THERAPEUTICS INC (GTHP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/18/2016 |
8-K
| Quarterly results |
| 05/19/2016 |
8-K
| Form 8-K - Current report |
| 03/15/2016 |
8-K
| Form 8-K - Current report |
| 11/13/2015 |
8-K
| Quarterly results|
Docs:
|
"Guided Therapeutics Reports Third Quarter 2015 Financial Results Highlights – • Completed first shipment of LuViva® Advanced Cervical Scans for the $14 million Turkish Ministry of Health order • Scheduled November 30 meeting with the FDA for the LuViva PMA application • Q4 revenue of $700,00 projected Norcross, GA - November 12, 2015 - Guided Therapeutics, Inc. , the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it reported third quarter financial results for the period ended September 30, 2015. Guided Therapeutics reported $94,000 in revenue for the three months ended September 30, 2015, compared to $262,000 for the same period in 2014. This decrease was primarily the result of lower shipments of 6 units of LuViva and 160...",
"Transcript of conference call on November 13, 2015" |
|
| 08/13/2015 |
8-K
| Quarterly results |
| 05/14/2015 |
8-K
| Quarterly results, Conference call transcript |
| 03/30/2015 |
8-K
| Quarterly results, Conference call transcript|
Docs:
|
"Guided Therapeutics Reports 2014 Results Key Highlights: • 2015 product sales forecast of over $3 million compared to 2014 product sales of $758,000 • Several key markets expected to ramp up screening efforts in 2015 • FDA response on amended LuViva PMA application expected to be imminent Norcross, GA -- Guided Therapeutics, Inc. today announced its operating results for the fourth quarter and year ended December 31, 2014. Revenue and other income for the fourth quarter ended December 31, 2014 was approximately $185,000, including approximately $172,000 in sales of LuViva® Advanced Cervical Scan devices and disposables and $13,000 from contract and grant income. Revenue for the quarter ended December 31, 2013 was comprised of product sales of approximately $53,000 and contract and grant i...",
"Transcript of Conference Call held on March 25, 2015" |
|
| 11/14/2014 |
8-K
| Quarterly results |
| 08/14/2014 |
8-K
| Quarterly results |
| 05/19/2014 |
8-K
| Quarterly results |
| 03/27/2014 |
8-K
| Quarterly results, Conference call transcript|
Docs:
|
"Key Highlights:",
"Transcript of Conference Call held on March 27, 2014",
"Extension for LuViva Advanced Cervical Scan NORCROSS, GA – Guided Therapeutics, Inc. today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur. “While we have drafted our responses to questions in the not approvable letter received in September, we feel it is in our best interest to meet with FDA before submission of the official response,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “These face-to-face meetings are an important part..." |
|
| 11/15/2013 |
8-K
| Quarterly results, Conference call transcript |
| 08/16/2013 |
8-K
| Quarterly results |
| 05/15/2013 |
8-K
| Quarterly results |
| 11/15/2012 |
8-K
| Form 8-K - Current report |
| 05/22/2012 |
8-K
| Form 8-K - Current report |
| 03/30/2012 |
8-K
| Form 8-K - Current report |
| 11/15/2011 |
8-K
| Form 8-K - Current report |
| 08/16/2011 |
8-K
| Form 8-K - Current report |
| 05/17/2011 |
8-K
| Form 8-K - Current report |
| 04/01/2011 |
8-K
| Quarterly results|
Docs:
|
"Assigned Task Agreement",
"Agreement for Collaboration in the Development of Sectroscopic technology",
"Guided Therapeutics Reports Fourth Quarter and Year End 2010 Results Key Highlights: · PMA process moving ahead with answers to FDA questions to be submitted in April · Barrett’s Esophagus technology approved to begin human clinical studies · Approximately $1 million raised from grant and warrants exercised Norcross, GA -- Guided Therapeutics, Inc. today announced its operating results for the fourth quarter and year ended December 31, 2010. Contract and grant revenue for the fourth quarter of 2010 was approximately $1,062,000 compared to revenue of approximately $550,000 in the fourth quarter of 2009. For the twelve months ended December 31, 2010, revenue was approximately $3.3 million versus approximately $1.6 million for 2009. The increase in revenue for the quarter and the year is prim...",
"Konica Minolta Opto, Inc. Extends Product Development Licensing Agreement with $750,000 Payment to Guided Therapeutics NORCROSS, GA – Guided Therapeutics, Inc. , developer of a rapid and painless biophotonic testing platform for the early detection of disease, today announced that Konica Minolta Opto, Inc. of Tokyo has extended its licensing agreement to co-develop non-invasive cancer detection products. Under terms of the agreement, Konica Minolta Opto will pay Guided Therapeutics a $750,000 fee to extend the agreement for one year. This is in addition to approximately $1.7 million the company expects to receive, over the course of the next 12 months, for the co-development of its first product in conjunction with Konica Minolta Opto for the detection and monitoring of esophageal pre-canc...",
"Conference call script" |
|
| 05/17/2010 |
8-K
| Form 8-K - Current report |
| 11/20/2007 |
8-K
| Form 8-K - Current report |
| 12/29/2006 |
8-K
| Form 8-K - Current report |
| 09/19/2006 |
8-K
| Form 8-K - Current report |
|
|